Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.

Naegelin Y, Rasenack M, Andelova M, Von Felten S, Fischer-Barnicol B, Amann M, Mehling M, Kappos L, Sprenger T, Derfuss T.

Mult Scler Relat Disord. 2018 Oct;25:14-20. doi: 10.1016/j.msard.2018.07.005. Epub 2018 Jul 6.

2.

Beat protectionism and emissions at a stroke.

Mehling MA, van Asselt H, Das K, Droege S.

Nature. 2018 Jul;559(7714):321-324. doi: 10.1038/d41586-018-05708-7. No abstract available.

PMID:
30013205
3.

Nano-scale microfluidics to study 3D chemotaxis at the single cell level.

Frick C, Dettinger P, Renkawitz J, Jauch A, Berger CT, Recher M, Schroeder T, Mehling M.

PLoS One. 2018 Jun 7;13(6):e0198330. doi: 10.1371/journal.pone.0198330. eCollection 2018.

4.

Response of high leaf-oil Arabidopsis thaliana plant lines to biotic or abiotic stress.

Yurchenko O, Kimberlin A, Mehling M, Koo AJ, Chapman KD, Mullen RT, Dyer JM.

Plant Signal Behav. 2018;13(5):e1464361. doi: 10.1080/15592324.2018.1464361. Epub 2018 Jun 4.

5.

Linking climate policies to advance global mitigation.

Mehling MA, Metcalf GE, Stavins RN.

Science. 2018 Mar 2;359(6379):997-998. doi: 10.1126/science.aar5988. No abstract available.

6.

Pricing not enough for deep carbon cuts.

Mehling M, Tvinnereim E.

Nature. 2017 Dec 14;552(7684):175. doi: 10.1038/d41586-017-08578-7. No abstract available.

PMID:
29239378
7.

Varicella zoster virus-specific T cell responses in untreated giant cell arteritis: comment on the article by England et al.

Bigler MB, Hirsiger JR, Recher M, Mehling M, Daikeler T, Berger CT.

Arthritis Rheumatol. 2018 Feb;70(2):318-320. doi: 10.1002/art.40363. Epub 2017 Dec 20. No abstract available.

8.

Locally Triggered Release of the Chemokine CCL21 Promotes Dendritic Cell Transmigration across Lymphatic Endothelia.

Vaahtomeri K, Brown M, Hauschild R, De Vries I, Leithner AF, Mehling M, Kaufmann WA, Sixt M.

Cell Rep. 2017 May 2;19(5):902-909. doi: 10.1016/j.celrep.2017.04.027.

9.

Characteristics of autoantibodies targeting 14-3-3 proteins and their association with clinical features in newly diagnosed giant cell arteritis.

Kistner A, Bigler MB, Glatz K, Egli SB, Baldin FS, Marquardsen FA, Mehling M, Rentsch KM, Staub D, Aschwanden M, Recher M, Daikeler T, Berger CT.

Rheumatology (Oxford). 2017 May 1;56(5):829-834. doi: 10.1093/rheumatology/kew469.

PMID:
28064210
10.

Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis.

Navarini AA, Hruz P, Berger CT, Hou TZ, Schwab C, Gabrysch A, Higgins R, Frede N, Padberg Sgier BC, Kämpe O, Burgener AV, Marquardsen F, Baldin F, Bigler M, Kistner A, Jauch A, Bignucolo O, Meyer B, Meienberg F, Mehling M, Jeker LT, Heijnen I, Daikeler TD, Gebbers JO, Grimbacher B, Sansom DM, Jeker R, Hess C, Recher M.

J Allergy Clin Immunol. 2017 Mar;139(3):1043-1046.e5. doi: 10.1016/j.jaci.2016.08.042. Epub 2016 Nov 28. No abstract available.

PMID:
27908448
11.

A microfluidic device for measuring cell migration towards substrate-bound and soluble chemokine gradients.

Schwarz J, Bierbaum V, Merrin J, Frank T, Hauschild R, Bollenbach T, Tay S, Sixt M, Mehling M.

Sci Rep. 2016 Nov 7;6:36440. doi: 10.1038/srep36440.

12.

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.

Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr.

13.

Severity of Autism Spectrum Disorders: Current Conceptualization, and Transition to DSM-5.

Mehling MH, Tassé MJ.

J Autism Dev Disord. 2016 Jun;46(6):2000-2016. doi: 10.1007/s10803-016-2731-7.

PMID:
26873143
14.

The Immune-Metabolic Basis of Effector Memory CD4+ T Cell Function under Hypoxic Conditions.

Dimeloe S, Mehling M, Frick C, Loeliger J, Bantug GR, Sauder U, Fischer M, Belle R, Develioglu L, Tay S, Langenkamp A, Hess C.

J Immunol. 2016 Jan 1;196(1):106-14. doi: 10.4049/jimmunol.1501766. Epub 2015 Nov 30.

15.

Tissue Distribution Dynamics of Human NK Cells Inferred from Peripheral Blood Depletion Kinetics after Sphingosine-1-Phosphate Receptor Blockade.

Mehling M, Burgener AV, Brinkmann V, Bantug GR, Dimeloe S, Hoenger G, Kappos L, Hess C.

Scand J Immunol. 2015 Nov;82(5):460-6. doi: 10.1111/sji.12347.

16.

Methylmercury Bioaccumulation in Stream Food Webs Declines with Increasing Primary Production.

Walters DM, Raikow DF, Hammerschmidt CR, Mehling MG, Kovach A, Oris JT.

Environ Sci Technol. 2015 Jul 7;49(13):7762-9. doi: 10.1021/acs.est.5b00911. Epub 2015 Jun 10.

PMID:
26018982
17.

Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection.

Berger CT, Greiff V, Mehling M, Fritz S, Meier MA, Hoenger G, Conen A, Recher M, Battegay M, Reddy ST, Hess C.

Hum Vaccin Immunother. 2015;11(2):391-6. doi: 10.1080/21645515.2015.1008930.

18.

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis.

Kappos L, Mehling M, Arroyo R, Izquierdo G, Selmaj K, Curovic-Perisic V, Keil A, Bijarnia M, Singh A, von Rosenstiel P.

Neurology. 2015 Mar 3;84(9):872-9. doi: 10.1212/WNL.0000000000001302. Epub 2015 Jan 30.

PMID:
25636714
19.

Real-time tracking, retrieval and gene expression analysis of migrating human T cells.

Mehling M, Frank T, Albayrak C, Tay S.

Lab Chip. 2015 Mar 7;15(5):1276-83. doi: 10.1039/c4lc01038h.

PMID:
25512266
20.

Impact of Choice on Social Outcomes of Adults with ASD.

Mehling MH, Tassé MJ.

J Autism Dev Disord. 2015 Jun;45(6):1588-602. doi: 10.1007/s10803-014-2312-6.

PMID:
25413143
21.

Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS.

Mehling M, Eichin D, Hafner P, Hönger G, Kappos L, Hess C.

Neurol Neuroimmunol Neuroinflamm. 2014 Sep 11;1(3):e28. doi: 10.1212/NXI.0000000000000028. eCollection 2014 Oct. No abstract available.

22.

Empirically derived model of social outcomes and predictors for adults with ASD.

Mehling MH, Tassé MJ.

Intellect Dev Disabil. 2014 Aug;52(4):282-95. doi: 10.1352/1934-9556-52.4.282.

PMID:
25061772
23.

Microfluidic cell culture.

Mehling M, Tay S.

Curr Opin Biotechnol. 2014 Feb;25:95-102. doi: 10.1016/j.copbio.2013.10.005. Epub 2013 Nov 12. Review.

PMID:
24484886
24.

Medication therapy management: teaming with pharmacists for improved patient care.

Brown W, Maack B, Mehling M.

JAAPA. 2013 Dec;26(12):40-3. doi: 10.1097/01.JAA.0000437823.61279.f2.

PMID:
24270034
25.

Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy.

Mehling M, Fritz S, Hafner P, Eichin D, Yonekawa T, Klimkait T, Lindberg RL, Kappos L, Hess C.

PLoS One. 2013 Nov 5;8(11):e78532. doi: 10.1371/journal.pone.0078532. eCollection 2013.

26.

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F.

Mult Scler. 2014 Apr;20(5):577-87. doi: 10.1177/1352458513503597. Epub 2013 Sep 5.

PMID:
24009164
27.

Homing frequency of human T cells inferred from peripheral blood depletion kinetics after sphingosine-1-phosphate receptor blockade.

Mehling M, Brinkmann V, Burgener AV, Gubser P, Luster AD, Kappos L, Hess C.

J Allergy Clin Immunol. 2013 May;131(5):1440-3.e7. doi: 10.1016/j.jaci.2012.12.1520. Epub 2013 Feb 21. No abstract available.

PMID:
23434284
28.

Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

Gensicke H, Leppert D, Yaldizli Ö, Lindberg RL, Mehling M, Kappos L, Kuhle J.

CNS Drugs. 2012 Jan 1;26(1):11-37. doi: 10.2165/11596920-000000000-00000. Review.

PMID:
22171583
29.

Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.

Mehling M, Kappos L, Derfuss T.

Curr Neurol Neurosci Rep. 2011 Oct;11(5):492-7. doi: 10.1007/s11910-011-0216-9. Review.

PMID:
21789537
30.

Hodgkin's Lymphoma and Paraneoplastic Phenomena in the Central Nervous System: A Case Report and Review of the Literature.

Vetter M, Tzankov A, Engert A, Mehling M, Herrmann R, Rochlitz C.

Case Rep Oncol. 2011 Feb 25;4(1):106-14. doi: 10.1159/000324922.

31.

Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.

Mehling M, Hilbert P, Fritz S, Durovic B, Eichin D, Gasser O, Kuhle J, Klimkait T, Lindberg RL, Kappos L, Hess C.

Ann Neurol. 2011 Feb;69(2):408-13. doi: 10.1002/ana.22352.

PMID:
21387383
32.

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.

Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A.

Neurology. 2011 Feb 22;76(8 Suppl 3):S20-7. doi: 10.1212/WNL.0b013e31820db341. Review.

PMID:
21339487
33.

Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.

Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, Anthony DC, Kappos L, Lindberg RL.

Neurology. 2011 Apr 5;76(14):1206-13. doi: 10.1212/WNL.0b013e31821432ff. Epub 2011 Feb 23.

PMID:
21346223
34.

Three cases of primary small vessel vasculitis of the skeletal muscle-an own entity.

Benz N, Daikeler T, Frank S, Mehling M, Tyndall A, Trendelenburg M.

BMJ Case Rep. 2011 Nov 8;2011. pii: bcr0820114631. doi: 10.1136/bcr.08.2011.4631.

35.

Images in clinical medicine. Dissociation of voluntary and emotional innervation after stroke.

Kappos L, Mehling M.

N Engl J Med. 2010 Oct 14;363(16):e25. doi: 10.1056/NEJMicm0900573. No abstract available.

36.

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.

Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L, Brinkmann V.

Neurology. 2010 Aug 3;75(5):403-10. doi: 10.1212/WNL.0b013e3181ebdd64. Epub 2010 Jun 30.

PMID:
20592255
37.

Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: implications for lesion pathogenesis.

Heidbrink C, Häusler SF, Buttmann M, Ossadnik M, Strik HM, Keller A, Buck D, Verbraak E, van Meurs M, Krockenberger M, Mehling M, Mittelbronn M, Laman JD, Wiendl H, Wischhusen J.

Brain Behav Immun. 2010 Aug;24(6):975-84. doi: 10.1016/j.bbi.2010.04.003. Epub 2010 Apr 10.

PMID:
20385225
38.

Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients.

Lindberg RL, Hoffmann F, Mehling M, Kuhle J, Kappos L.

Eur J Immunol. 2010 Mar;40(3):888-98. doi: 10.1002/eji.200940032.

39.

A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.

Kuhle J, Regeniter A, Leppert D, Mehling M, Kappos L, Lindberg RL, Petzold A.

J Neuroimmunol. 2010 Mar 30;220(1-2):114-9. doi: 10.1016/j.jneuroim.2010.01.004. Epub 2010 Feb 1.

PMID:
20117845
40.

Rigidity of retinal vessels in patients with multiple sclerosis.

Kochkorov A, Gugleta K, Kavroulaki D, Katamay R, Weier K, Mehling M, Kappos L, Flammer J, Orgül S.

Klin Monbl Augenheilkd. 2009 Apr;226(4):276-9. doi: 10.1055/s-0028-1109291. Epub 2009 Apr 21.

PMID:
19384782
41.

Retinal vessels in patients with multiple sclerosis: baseline diameter and response to flicker light stimulation.

Gugleta K, Kochkorov A, Kavroulaki D, Katamay R, Weier K, Mehling M, Kappos L, Flammer J, Orgül S.

Klin Monbl Augenheilkd. 2009 Apr;226(4):272-5. doi: 10.1055/s-0028-1109289. Epub 2009 Apr 21.

PMID:
19384781
42.

Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis.

Kuhle J, Lindberg RL, Regeniter A, Mehling M, Steck AJ, Kappos L, Czaplinski A.

Eur J Neurol. 2009 Jun;16(6):771-4. doi: 10.1111/j.1468-1331.2009.02560.x. Epub 2009 Feb 19.

PMID:
19236470
43.

A modern approach to CSF analysis: pathophysiology, clinical application, proof of concept and laboratory reporting.

Regeniter A, Kuhle J, Mehling M, Möller H, Wurster U, Freidank H, Siede WH.

Clin Neurol Neurosurg. 2009 May;111(4):313-8. doi: 10.1016/j.clineuro.2008.12.004. Epub 2009 Jan 30. Review.

PMID:
19185983
44.

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL, Kappos L.

Neurology. 2008 Oct 14;71(16):1261-7. doi: 10.1212/01.wnl.0000327609.57688.ea.

PMID:
18852441
45.

Pattern of macular thickness changes measured by ocular coherence tomography in patients with multiple sclerosis.

Gugleta K, Mehling M, Kochkorov A, Grieshaber M, Katamay R, Flammer J, Orgül S, Kappos L.

Klin Monbl Augenheilkd. 2008 May;225(5):408-12. doi: 10.1055/s-2008-1027253.

PMID:
18454382
46.

Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.

Mehling M, Drechsler H, Kuhle J, Hardmeier M, Doerries R, Ruegg S, Gass A.

J Neurovirol. 2008 Jan;14(1):78-84. doi: 10.1080/13550280701793940.

PMID:
18300078
47.

10 most commonly asked questions about cerebrospinal fluid characteristics in demyelinating disorders of the central nervous system.

Mehling M, Kuhle J, Regeniter A.

Neurologist. 2008 Jan;14(1):60-5. doi: 10.1097/NRL.0b013e31815ac523. Review. No abstract available.

PMID:
18195662
48.

WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?

Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, Wiendl H.

Acta Neuropathol. 2007 Aug;114(2):111-9. Epub 2007 May 31.

PMID:
17541610
49.

Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF.

Kuhle J, Lindberg RL, Regeniter A, Mehling M, Hoffmann F, Reindl M, Berger T, Radue EW, Leppert D, Kappos L.

J Neurol. 2007 Feb;254(2):160-8.

PMID:
17334662
50.

Lack of association between antimyelin antibodies and progression to multiple sclerosis.

Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R.

N Engl J Med. 2007 Jan 25;356(4):371-8.

Supplemental Content

Loading ...
Support Center